nach oben

Journal of Nephrology

Erschienen in:

04.05.2023 | Review

What has vaccination against COVID-19 in CKD patients taught us?

verfasst von: Mattia Rossi, Giuseppina Pessolano, Giovanni Gambaro

Erschienen in: Journal of Nephrology | Ausgabe 5/2023

Einloggen, um Zugang zu erhalten

Abstract

Effective vaccination strategies are of crucial importance to protecting patients who are vulnerable to infections, such as patients with chronic kidney disease. This is because the decreased efficiency of the immune system in chronic kidney disease impairs vaccine-induced immunisation. COVID-19 has prompted investigation of the immune response to SARS-CoV-2 vaccines in chronic kidney disease and in kidney transplant recipients in an effort to improve efficacy. The seroconversion rate after two vaccine doses is reduced, especially in kidney transplant recipients. Furthermore, although the seroconversion rate in chronic kidney disease patients is as high as in healthy subjects, anti-spike antibody titres are lower than in healthy vaccinated individuals, and these titres decrease rapidly. Although the vaccine-induced anti-spike antibody titre correlates with neutralising antibody levels and with protection against COVID-19, the protective prognostic significance of their titre is decreased due to the emergence of SARS-CoV-2 variants other than the Wuhan index virus against which the original vaccines were produced. Cellular immunity is also relevant, and because of cross-reactivity to the spike protein, epitopes of different viral variants confer protection against newly emerging variants of SARS-CoV-2. A multi-dose vaccination strategy is the most effective way to obtain a sufficient serological response. In kidney transplant recipients, a 5-week discontinuation period from antimetabolite drugs in concomitance with vaccine administration may also increase the vaccine’s efficacy. The newly acquired knowledge obtained from COVID-19 vaccination is of general interest for the success of other vaccinations in chronic kidney disease patients.

Noordzij M, Duivenvoorden R, Pena MJ, de Vries H, Kieneker LM, collaborative ERACODA authors, (2020) ERACODA: the European database collecting clinical information of patients on kidney replacement therapy with COVID-19. Nephrol Dial Transplant 35:2023–2025. https://doi.org/10.1093/ndt/gfaa179CrossRefPubMed

Gansevoort RT, Hilbrands LB (2020) CKD is a key risk factor for COVID-19 mortality. Nat Rev Nephrol 16:705–706. https://doi.org/10.1038/s41581-020-00349-4CrossRefPubMedPubMedCentral

Puchalska-Reglińska E, Dębska-Ślizień A, Biedunkiewicz B et al (2021) Extremely high mortality rates among hemodialysis patients with COVID-19 before the era of SARS-CoV-2 vaccination: results from a large database from the North of Poland. Pol Arch Intern Med 131(7–8):643–648. https://doi.org/10.20452/pamw.16028CrossRefPubMed

Qin CX, Moore LW, Anjan S et al (2021) Risk of Breakthrough SARS-CoV-2 Infections in Adult Transplant Recipients. Transplantation 105(11):e265–e266. https://doi.org/10.1097/TP.0000000000003907CrossRefPubMedPubMedCentral

Nyberg T, Ferguson NM, Nash SG, et al (2022) Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England: a cohort study. Lancet 399(10332):1303–1312.https://doi.org/10.1016/S0140-6736(22)00462-7

Shields AM, Tadros S, Al-Hakim A, et al (2022) Impact of vaccination on hospitalization and mortality from COVID-19 in patients with primary and secondary immunodeficiency: The United Kingdom experience. Front Immunol 13:984376. https://doi.org/10.3389/fimmu.2022.984376

Babel N, Hugo C, Westhoff TH (2022) Vaccination in patients with kidney failure: lessons from COVID-19. Nat Rev Nephrol 18(11):708–723. https://doi.org/10.1038/s41581-022-00617-5CrossRefPubMedPubMedCentral

Reddy S, Chitturi C, Yee J (2019) Vaccination in Chronic Kidney Disease. Adv Chronic Kidney Dis 26(1):72–78. https://doi.org/10.1053/j.ackd.2018.10.002CrossRefPubMed

Kolland M, Riedl R, Bachler B et al (2022) Decreased response to the mRNA anti-SARS-CoV-2 vaccine in hepatitis B vaccine non-responders and frail patients treated with peritoneal dialysis. Nephrol Dial Transplant 37(6):1188–1190. https://doi.org/10.1093/ndt/gfac031CrossRefPubMed

10.

Danthu C, Hantz S, Dahlem A et al (2021) Humoral Response after SARS-CoV-2 mRNA Vaccination in a Cohort of Hemodialysis Patients and Kidney Transplant Recipients. J Am Soc Nephrol 32(9):2153–2158. https://doi.org/10.1681/ASN.2021040490CrossRefPubMedPubMedCentral

11.

Teijaro RJ, Farber D (2021) COVID-19 vaccines: modes of immune activation and future challenges. Nat Rev Immunol 21:195–197. https://doi.org/10.1038/s41577-021-00526-xCrossRefPubMedPubMedCentral

12.

Israelow B, Mao T, Klein J, et al (2021) Adaptive immune determinants of viral clearance and protection in mouse models of SARS-CoV-2. Sci Immunol 6(64):eabl4509. https://doi.org/10.1126/sciimmunol.abl4509

13.

Sibbel S, McKeon K, Luo J et al (2022) Real-World Effectiveness and Immunogenicity of BNT162b2 and mRNA-1273 SARS-CoV-2 Vaccines in Patients on Hemodialysis. J Am Soc Nephrol 33(1):49–57. https://doi.org/10.1681/ASN.2021060778CrossRefPubMedPubMedCentral

14.

Oliver MJ, Thomas D, Balamchi S et al (2022) Vaccine effectiveness against SARS-CoV-2 infection and severe outcomes in the maintenance dialysis population in Ontario. Canada J Am Soc Nephrol 33(4):839–849. https://doi.org/10.1681/ASN.2021091262CrossRefPubMed

15.

El Karoui K, Hourmant M, Ayav C et al (2022) Vaccination and COVID-19 dynamics in dialysis patients. Clin J Am Soc Nephrol 17(3):395–402. https://doi.org/10.2215/CJN.10300721CrossRefPubMedPubMedCentral

16.

Aslam S, Adler E, Mekeel K, Little SJ (2021) Clinical effectiveness of COVID-19 vaccination in solid organ transplant recipients. Transpl Infect Dis23(5):e13705. https://doi.org/10.1111/tid.13705

17.

Lacson E Jr, Argyropoulos CP, Manley HJ et al (2021) Immunogenicity of SARS-CoV-2 vaccine in dialysis. J Am Soc Nephrol 32(11):2735–2742. https://doi.org/10.1681/ASN.2021040432CrossRefPubMedPubMedCentral

18.

Van Praet J, Reynders M, De Bacquer D, et al (2021) Predictors and Dynamics of the Humoral and Cellular Immune Response to SARS-CoV-2 mRNA Vaccines in Hemodialysis Patients: A Multicenter Observational Study [published online ahead of print, 2021 Sep 29]. J Am Soc Nephrol 32(12):3208–3220. https://doi.org/10.1681/ASN.2021070908

19.

Quiroga B, Soler MJ, Ortiz A et al (2022) Loss of humoral response 3 months after SARS-CoV-2 vaccination in the CKD spectrum: the multicentric SENCOVAC study. Nephrol Dial Transplant 37(5):994–999. https://doi.org/10.1093/ndt/gfac007CrossRefPubMed

20.

Quiroga B, Soler MJ, Ortiz A et al (2022) Safety and immediate humoral response of COVID-19 vaccines in chronic kidney disease patients: the SENCOVAC study. Nephrol Dial Transplant 37(10):1868–1878. https://doi.org/10.1093/ndt/gfab313CrossRefPubMed

21.

Quiroga B, Soler MJ, Ortiz A et al (2022) Humoral response to third dose of SARS-CoV-2 vaccines in the CKD spectrum. Clin J Am Soc Nephrol 17(6):872–876. https://doi.org/10.2215/CJN.01770222CrossRefPubMedPubMedCentral

22.

Hsu CM, Weiner DE, Manley HJ et al (2022) Seroresponse to SARS-CoV-2 vaccines among maintenance dialysis patients over 6 Months. Clin J Am Soc Nephrol 17(3):403–413. https://doi.org/10.2215/CJN.12250921CrossRefPubMedPubMedCentral

23.

Karakizlis H, Agarwal V, Aly M, et al (2022) Humoral and cellular immune responses to the mRNA-1273 SARS-CoV-2 vaccine booster in patients on maintenance dialysis [published online ahead of print, 2022 Jun 22]. J Nephrol. 1–4. https://doi.org/10.1007/s40620-022-01371-4

24.

Boyarsky BJ, Werbel WA, Avery RK et al (2021) Antibody response to 2-Dose SARS-CoV-2 mRNA vaccine series in solid organ transplant recipients. JAMA 325(21):2204–2206. https://doi.org/10.1001/jama.2021.7489CrossRefPubMedPubMedCentral

25.

Yau K, Chan CT, Abe KT et al (2022) Differences in mRNA-1273 (Moderna) and BNT162b2 (Pfizer-BioNTech) SARS-CoV-2 vaccine immunogenicity among patients undergoing dialysis. CMAJ 194(8):E297–E305. https://doi.org/10.1503/cmaj.211881CrossRefPubMedPubMedCentral

26.

Verleye A, Wijtvliet V, Abrams S et al (2022) Seroconversion rate after primary vaccination with two doses of BNT162b2 versus mRNA-1273 in solid organ transplant recipients: a systematic review and meta-analysis. Nephrol Dial Transplant 37(8):1566–1575. https://doi.org/10.1093/ndt/gfac174CrossRefPubMed

27.

Sanders JF, Bemelman FJ, Messchendorp AL et al (2022) The RECOVAC immune-response study: the immunogenicity, tolerability, and safety of COVID-19 vaccination in patients with chronic kidney disease, on dialysis, or living with a kidney transplant. Transplantation 106(4):821–834. https://doi.org/10.1097/TP.0000000000003983CrossRefPubMed

28.

Grupper A, Sharon N, Finn T et al (2021) Humoral response to the Pfizer BNT162b2 vaccine in patients undergoing maintenance hemodialysis. Clin J Am Soc Nephrol 16(7):1037–1042. https://doi.org/10.2215/CJN.03500321CrossRefPubMedPubMedCentral

29.

Chavarot N, Ouedrani A, Marion O et al (2021) Poor Anti-SARS-CoV-2 humoral and T-cell responses after 2 injections of mRNA vaccine in kidney transplant recipients treated with belatacept. Transplantation 105(9):e94–e95. https://doi.org/10.1097/TP.0000000000003784CrossRefPubMed

30.

Korth J, Jahn M, Dorsch O, et al (2021) Impaired Humoral Response in Renal Transplant Recipients to SARS-CoV-2 Vaccination with BNT162b2 (Pfizer-BioNTech). Viruses 13(5):756. Published 2021 Apr 25. https://doi.org/10.3390/v13050756

31.

Rozen-Zvi B, Yahav D, Agur T et al (2021) Antibody response to SARS-CoV-2 mRNA vaccine among kidney transplant recipients: a prospective cohort study. Clin Microbiol Infect 27(8):1173.e1-1173.e4. https://doi.org/10.1016/j.cmi.2021.04.028CrossRefPubMed

32.

Benotmane I, Gautier-Vargas G, Cognard N et al (2021) Low immunization rates among kidney transplant recipients who received 2 doses of the mRNA-1273 SARS-CoV-2 vaccine. Kidney Int 99:1498–1500. https://doi.org/10.1016/j.kint.2021.04.005CrossRefPubMedPubMedCentral

33.

Manothummetha K, Chuleerarux N, Sanguankeo A, et al (2022) Immunogenicity and Risk Factors Associated With Poor Humoral Immune Response of SARS-CoV-2 Vaccines in Recipients of Solid Organ Transplant: A Systematic Review and Meta-Analysis. JAMA Netw Open 5(4):e226822. Published 2022 Apr 1. https://doi.org/10.1001/jamanetworkopen.2022.6822

34.

Espi M, Charmetant X, Barba T et al (2022) A prospective observational study for justification, safety, and efficacy of a third dose of mRNA vaccine in patients receiving maintenance hemodialysis. Kidney Int 101(2):390–402. https://doi.org/10.1016/j.kint.2021.10.040CrossRefPubMed

35.

Lesny P, Anderson M, Cloherty G et al (2021) Immunogenicity of a first dose of mRNA- or vector-based SARS-CoV-2 vaccination in dialysis patients: a multicenter prospective observational pilot study. J Nephrol 34(4):975–983. https://doi.org/10.1007/s40620-021-01076-0CrossRefPubMedPubMedCentral

36.

Espi M, Koppe L, Fouque D, Thaunat O (2020) Chronic Kidney Disease-Associated Immune Dysfunctions: Impact of Protein-Bound Uremic Retention Solutes on Immune Cells. Toxins (Basel) 12(5):300. Published 2020 May 6. https://doi.org/10.3390/toxins12050300

37.

Rincon-Arevalo H, Choi M, Stefanski AL, et al (2021) Impaired humoral immunity to SARS-CoV-2 BNT162b2 vaccine in kidney transplant recipients and dialysis patients. Sci Immunol 6(60):eabj1031. https://doi.org/10.1126/sciimmunol.abj1031

38.

Kovacic V, Sain M, Vukman V (2002) Efficient haemodialysis improves the response to hepatitis B virus vaccination. Intervirology 45(3):172–176. https://doi.org/10.1159/000065873CrossRefPubMed

39.

Sattler A, Schrezenmeier E, Weber UA, et al (2021)) Impaired humoral and cellular immunity after SARS-CoV-2 BNT162b2 (tozinameran) prime-boost vaccination in kidney transplant recipients. J Clin Invest 131(14):e150175. https://doi.org/10.1172/JCI150175

40.

Cucchiari D, Egri N, Rodriguez-Espinosa D, et al (2022) Humoral and cellular immune responses after a 3-dose course of mRNA-1273 COVID-19 vaccine in kidney transplant recipients: a prospective cohort study. Transplant Direct 8(11):e1389. Published 2022 Oct 7. https://doi.org/10.1097/TXD.0000000000001389

41.

Sahin U, Muik A, Vogler I et al (2021) BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans. Nature 595(7868):572–577. https://doi.org/10.1038/s41586-021-03653-6CrossRefPubMed

42.

Schrezenmeier E, Rincon-Arevalo H, Stefanski AL et al (2021) B and T cell responses after a third dose of SARS-CoV-2 vaccine in kidney transplant recipients. J Am Soc Nephrol 32(12):3027–3033. https://doi.org/10.1681/ASN.2021070966CrossRefPubMedPubMedCentral

43.

Bertoletti A, Le Bert N, Tan AT (2022) SARS-CoV-2-specific T cells in the changing landscape of the COVID-19 pandemic. Immunity 55(10):1764–1778. https://doi.org/10.1016/j.immuni.2022.08.008CrossRefPubMedPubMedCentral

44.

Skelly DT, Harding AC, Gilbert-Jaramillo J et al (2021) Two doses of SARS-CoV-2 vaccination induce robust immune responses to emerging SARS-CoV-2 variants of concern. Nat Commun 12(1):5061. https://doi.org/10.1038/s41467-021-25167-5CrossRefPubMedPubMedCentral

45.

McMahan K, Yu J, Mercado NB et al (2021) Correlates of protection against SARS-CoV-2 in rhesus macaques. Nature 590(7847):630–634. https://doi.org/10.1038/s41586-020-03041-6CrossRefPubMed

46.

Tangye SG; COVID Human Genetic Effort consortium. Impact of SARS-CoV-2 infection and COVID-19 on patients with inborn errors of immunity. J Allergy Clin Immunol 2022 Dec 13:S0091–6749(22)01568–8. https://doi.org/10.1016/j.jaci.2022.11.010.

47.

Le Bert N, Tan AT, Kunasegaran K et al (2020) SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls. Nature 584(7821):457–462. https://doi.org/10.1038/s41586-020-2550-zCrossRefPubMed

48.

Anft M, Blazquez-Navarro A, Stervbo U et al (2021) Detection of pre-existing SARS-CoV-2-reactive T cells in unexposed renal transplant patients. J Nephrol 34(4):1025–1037. https://doi.org/10.1007/s40620-021-01092-0CrossRefPubMedPubMedCentral

49.

Thieme CJ, Blazquez-Navarro A, Safi L, et al (2021) Impaired Humoral but Substantial Cellular Immune Response to Variants of Concern B1.1.7 and B.1.351 in Hemodialysis Patients after Vaccination with BNT162b2. J Am Soc Nephrol 32(11):2725–2727. https://doi.org/10.1681/ASN.2021050672

50.

Imhof C, Messchendorp AL, van der Heiden M, et al (2022) SARS-CoV-2 Spike-specific IFN-γ T-cell Response After COVID-19 Vaccination in Patients With Chronic Kidney Disease, on Dialysis, or Living With a Kidney Transplant. Transplant Direct 8(11):e1387. Published 2022 Oct 18. https://doi.org/10.1097/TXD.0000000000001387

51.

Brunelli SM, Sibbel S, Karpinski S, et al (2022) Comparative Effectiveness of mRNA-based BNT162b2 Vaccine versus Adenovirus Vector-Based Ad26.COV2.S Vaccine for the Prevention of COVID-19 among Dialysis Patients. J Am Soc Nephrol 33(4):688–697. https://doi.org/10.1681/ASN.2021101395

52.

Bell S, Campbell J, Lambourg E et al (2022) The impact of vaccination on incidence and outcomes of SARS-CoV-2 infection in patients with kidney failure in Scotland. J Am Soc Nephrol 33:677–686. https://doi.org/10.1681/ASN.2022010046CrossRefPubMedPubMedCentral

53.

Hall VG, Ferreira VH, Ku T et al (2021) Randomized trial of a third dose of mRNA-1273 vaccine in transplant recipients. N Engl J Med 385(13):1244–1246. https://doi.org/10.1056/NEJMc2111462CrossRefPubMed

54.

Quiroga B, Soler MJ, Ortiz A, et al (2022) Humoral response after the fourth dose of the SARS-CoV-2 vaccine in the CKD spectrum: a prespecified analysis of the SENCOVAC study [published online ahead of print, 2022 Nov 24]. Nephrol Dial Transplant ;gfac307. https://doi.org/10.1093/ndt/gfac307

55.

Osmanodja B, Ronicke S, Budde K et al (2022) Serological response to three, four and five doses of SARS-CoV-2 vaccine in kidney transplant recipients. J Clin Med 11(9):2565. https://doi.org/10.3390/jcm11092565CrossRefPubMedPubMedCentral

56.

Munro APS, Janani L, Cornelius V, et al (2021) Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial [published correction appears in Lancet. 2021 Dec 18;398(10318):2246]. Lancet. 398(10318):2258-2276. https://doi.org/10.1016/S0140-6736(21)02717-3

57.

Meijers B, Goedgezelschap A, Peeters D et al (2022) Heterologous versus homologous triple anti-COVID-19 vaccine regimens in patients on maintenance haemodialysis. Nephrol Dial Transplant 37(7):1384–1386. https://doi.org/10.1093/ndt/gfac033CrossRefPubMed

58.

Kho MML, Messchendorp AL, Frölke SC, et al (2022) Alternative strategies to increase the immunogenicity of COVID-19 vaccines in kidney transplant recipients not responding to two or three doses of an mRNA vaccine (RECOVAC): a randomised clinical trial [published online ahead of print, 2022 Oct 27]. Lancet Infect Dis. 2022;S1473–3099(22)00650–8. https://doi.org/10.1016/S1473-3099(22)00650-8

59.

Reindl-Schwaighofer R, Heinzel A, Mayrdorfer M et al (2022) Comparison of SARS-CoV-2 antibody response 4 weeks after homologous vs heterologous third vaccine dose in kidney transplant recipients: a randomized clinical trial. JAMA Intern Med 182(2):165–171. https://doi.org/10.1001/jamainternmed.2021.7372CrossRefPubMed

60.

Irrgang P, Gerling J, Kocher K, et al (2023) Class switch toward noninflammatory, spike-specific IgG4 antibodies after repeated SARS-CoV-2 mRNA vaccination. Sci Immunol 2023 Jan 27;8(79):eade2798. https://doi.org/10.1126/sciimmunol.ade2798.

61.

Buhre JS, Pongracz T, Künsting I et al (2023) mRNA vaccines against SARS-CoV-2 induce comparably low long-term IgG Fc galactosylation and sialylation levels but increasing long-term IgG4 responses compared to an adenovirus-based vaccine. Front Immunol 13:1020844. https://doi.org/10.3389/fimmu.2022.1020844CrossRefPubMedPubMedCentral

62.

Allison AC (2005) Mechanisms of action of mycophenolate mofetil. Lupus 14(Suppl 1):s2–s8. https://doi.org/10.1191/0961203305lu2109oaCrossRefPubMed

63.

Furer V, Eviatar T, Zisman D, et al (2021) Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study [published correction appears in Ann Rheum Dis. 2022 Jul;81(7):e133]. Ann Rheum Dis 80(10):1330–1338. https://doi.org/10.1136/annrheumdis-2021-220647

64.

Grupper A, Rabinowich L, Schwartz D et al (2021) Reduced humoral response to mRNA SARS-CoV-2 BNT162b2 vaccine in kidney transplant recipients without prior exposure to the virus. Am J Transpl 21(8):2719–2726. https://doi.org/10.1111/ajt.16615CrossRef

65.

Al Fatly Z, Betjes MGH, Messchendorp AL et al (2022) COVID-19 vaccination response in kidney transplant recipients with and without mycophenolate mofetil: follow-up of a randomized controlled trial. Kidney Int Rep 7(6):1433–1434. https://doi.org/10.1016/j.ekir.2022.04.002CrossRefPubMedPubMedCentral

66.

Mulley WR, Visvanathan K, Hurt AC et al (2012) Mycophenolate and lower graft function reduce the seroresponse of kidney transplant recipients to pandemic H1N1 vaccination. Kidney Int 82:212–219. https://doi.org/10.1038/ki.2012.106CrossRefPubMed

67.

Schrezenmeier E, Rincon-Arevalo H, Jens A, et al (2022) Temporary antimetabolite treatment hold boosts SARS-CoV-2 vaccination-specific humoral and cellular immunity in kidney transplant recipients. JCI Insight 7(9):e157836. Published 2022 May 9. https://doi.org/10.1172/jci.insight.157836

68.

Connolly CM, Chiang TP, Boyarsky BJ et al (2022) Temporary hold of mycophenolate augments humoral response to SARS-CoV-2 vaccination in patients with rheumatic and musculoskeletal diseases: a case series. Ann Rheum Dis 81(2):293–295. https://doi.org/10.1136/annrheumdis-2021-221252CrossRefPubMed

69.

Kantauskaite M, Müller L, Hillebrandt J, et al (2022) Immune response to third SARS-CoV-2 vaccination in seronegative kidney transplant recipients: Possible improvement by mycophenolate mofetil reduction. Clin Transplant. 36(11):e14790. https://doi.org/10.1111/ctr.14790

70.

Chavarot N, Morel A, Leruez-Ville M et al (2021) Weak antibody response to three doses of mRNA vaccine in kidney transplant recipients treated with belatacept. Am J Transpl 21(12):4043–4051. https://doi.org/10.1111/ajt.16814CrossRef

71.

Netti GS, Infante B, Troise D et al (2022) mTOR inhibitors improve both humoral and cellular response to SARS-CoV-2 messenger RNA BNT16b2 vaccine in kidney transplant recipients. Am J Transpl 22(5):1475–1482. https://doi.org/10.1111/ajt.16958CrossRef

72.

Lammert A, Schnuelle P, Rabenau HF, et al (2022) SARS-CoV-2 Vaccination in Kidney Transplant Recipients-Stratified Analysis of the Humoral Immune Response. Transplant Direct 8(11):e1384. Published 2022 Oct 14. https://doi.org/10.1097/TXD.0000000000001384

73.

Khoury DS, Cromer D, Reynaldi A et al (2021) Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med 27(7):1205–1211. https://doi.org/10.1038/s41591-021-01377-8CrossRefPubMed

74.

Jahrsdörfer B, Kroschel J, Ludwig C et al (2021) Independent side-by-side validation and comparison of 4 serological platforms for SARS-CoV-2 antibody testing. J Infect Dis 223(5):796–801. https://doi.org/10.1093/infdis/jiaa656CrossRefPubMed

75.

Wand O, Nacasch N, Fadeela A, et al (2022)Humoral response and breakthrough infections with SARS-CoV-2 B.1.617.2 variant in vaccinated maintenance hemodialysis patients. J Nephrol 35(5):1479–1487. https://doi.org/10.1007/s40620-022-01245-9

76.

Anand S, Montez-Rath ME, Han J et al (2022) SARS-CoV-2 vaccine antibody response and breakthrough infection in patients receiving dialysis. Ann Intern Med 175(3):371–378. https://doi.org/10.7326/M21-4176CrossRefPubMed

77.

Caillard S, Chavarot N, Bertrand D et al (2021) Occurrence of severe COVID-19 in vaccinated transplant patients. Kidney Int 100(2):477–479. https://doi.org/10.1016/j.kint.2021.05.011CrossRefPubMedPubMedCentral

78.

Boudhabhay I, Serris A, Servais A et al (2022) COVID-19 outbreak in vaccinated patients from a haemodialysis unit: antibody titres as a marker of protection from infection. Nephrol Dial Transplant 37(7):1357–1365. https://doi.org/10.1093/ndt/gfac016CrossRefPubMed

79.

Pillai S. (2023) Is it bad, is it good, or is IgG4 just misunderstood? Sci Immunol, Ahead of Print https://doi.org/10.1126/sciimmunol.adg7327

80.

Andrews N, Tessier E, Stowe J et al (2022) Duration of protection against mild and severe disease by Covid-19 vaccines. N Engl J Med 386:340–350CrossRefPubMed

81.

Perkins GB, Tunbridge M, Salehi T et al (2022) Concurrent vaccination of kidney transplant recipients and close household cohabitants against COVID-19. Kidney Int 101(5):1077–1080. https://doi.org/10.1016/j.kint.2022.02.015CrossRefPubMedPubMedCentral

82.

Medigeshi GR, Batra G, Murugesan DR, et al (2022) Sub-optimal neutralisation of omicron (B.1.1.529) variant by antibodies induced by vaccine alone or SARS-CoV-2 Infection plus vaccine (hybrid immunity) post 6-months. EBioMedicine 78:103938. https://doi.org/10.1016/j.ebiom.2022.103938

83.

Benotmane I, Velay A, Gautier-Vargas G et al (2022) Pre-exposure prophylaxis with 300 mg Evusheld elicits limited neutralizing activity against the Omicron variant. Kidney Int 102(2):442–444. https://doi.org/10.1016/j.kint.2022.05.008CrossRefPubMedPubMedCentral

84.

Yetmar ZA, Bhaimia E, Razonable RR (2022) Antispike monoclonal antibodies for prevention and treatment of coronavirus disease-2019 in solid organ transplant recipients. Yetmar ZA et al. Curr Opin Organ Transplant 27:269–276. https://doi.org/10.1097/MOT.0000000000000981

85.

Seija M, Rammauro F, Santiago J et al (2021) Comparison of antibody response to SARS-CoV-2 after two doses of inactivated virus and BNT162b2 mRNA vaccines in kidney transplant. Clin Kidney J 15(3):527–533. https://doi.org/10.1093/ckj/sfab291CrossRefPubMedPubMedCentral

86.

Zimmermann P, Curtis N (2019) Factors that influence the immune response to vaccination. Clin Microbiol Rev 32:e00084-e118. https://doi.org/10.1128/CMR.00084-18CrossRefPubMedPubMedCentral

87.

Palucka K, Banchereau J, Mellman I (2010) Designing vaccines based on biology of human dendritic cell subsets. Immunity 33:464–478. https://doi.org/10.1016/j.immuni.2010.10.007CrossRefPubMedPubMedCentral

88.

Roozen GVT, Prins MLM, van Binnendijk R et al (2022) Safety and Immunogenicity of intradermal fractional dose administration of the mRNA-1273 vaccine: a proof-of-concept study. Ann Intern Med 175(12):1771–1774. https://doi.org/10.7326/M22-2089CrossRefPubMed

89.

Willicombe M, Scanlon M, Loud F, Lightstone L (2022) Should we be clinically assessing antibody responses to covid vaccines in immunocompromised people? BMJ 377:o966. https://doi.org/10.1136/bmj.o966

Titel: What has vaccination against COVID-19 in CKD patients taught us?
verfasst von: Mattia Rossi
Giuseppina Pessolano
Giovanni Gambaro
Publikationsdatum: 04.05.2023
Verlag: Springer International Publishing
Erschienen in: Journal of Nephrology / Ausgabe 5/2023
Print ISSN: 1121-8428
Elektronische ISSN: 1724-6059
DOI: https://doi.org/10.1007/s40620-023-01640-w

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

17.05.2024 Plötzlicher Herztod Nachrichten

Ein signifikanter Anteil der Fälle von plötzlichem Herztod ist genetisch bedingt. Um ihre Verwandten vor diesem Schicksal zu bewahren, sollten jüngere Personen, die plötzlich unerwartet versterben, ausnahmslos einer Autopsie unterzogen werden.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

17.05.2024 Vorhofflimmern Nachrichten

Nicht nur ein vergrößerter, sondern auch ein kleiner linker Ventrikel ist bei Vorhofflimmern mit einer erhöhten Komplikationsrate assoziiert. Der Zusammenhang besteht nach Daten aus China unabhängig von anderen Risikofaktoren.

Semaglutid bei Herzinsuffizienz: Wie erklärt sich die Wirksamkeit?

17.05.2024 Herzinsuffizienz Nachrichten

Bei adipösen Patienten mit Herzinsuffizienz des HFpEF-Phänotyps ist Semaglutid von symptomatischem Nutzen. Resultiert dieser Benefit allein aus der Gewichtsreduktion oder auch aus spezifischen Effekten auf die Herzinsuffizienz-Pathogenese? Eine neue Analyse gibt Aufschluss.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2023

Associations of health literacy with self-management behaviours and health outcomes in chronic kidney disease: a systematic review

Hydroxocobalamin-induced oxalate nephropathy after smoke inhalation

COVID-19 disease in peritoneal dialysis patients: a single centre experience from India

Exploring biopsychosocial correlates of pregnancy risk and pregnancy intention in women with chronic kidney disease

Renal Satellite Units: a step to reduce the miseries of dialysis patients in the poverty-afflicted Pakistani population